China, Merck and HPV
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
The stock's fall snapped a two-day winning streak.
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall ...
Hosted on MSN6h
What to Expect From Merck & Co.'s Q4 2024 Earnings ReportWith a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback